OBJECTIVE. The paradigm of theranostics is based on tailoring therapy for the purpose of
optimizing outcomes. This principle is being applied to radioactive iodine therapy …

Thyroid cancers require complex and heterogeneous therapies with different impacts on
renal function. In our systematic literature review, we analyzed several aspects: renal …

This paper reports a very high capacity and recyclable Mg-Co-Al-layered double
hydroxide@ gC 3 N 4 nanocomposite as the new adsorbent for remediation of radioisotope …

The treatment of differentiated thyroid cancer continues to move away from a 'one size fits
all'approach to a process of tailored therapeutic decision-making that incorporates disease …

Background Patients with chronic kidney disease (CKD) may need to have their
radiopharmaceutical dosage adjusted to prevent adverse effects and poor outcomes, but …

Introduction: It is not clear whether high-activity radioactive iodine (131 I) treatment will affect
renal function. This study aimed to investigate the effects of high-activity 131 I treatment on …

Differentiated thyroid cancer (DTC) is commonly treated first with a partial or complete
thyroidectomy, followed by radioiodine (RAI) ablative therapy to eliminate remaining cancer …

Purpose Radioactive iodine (RAI) is used to treat thyroid cancer patients with a clear
paradigm for most patients. End-stage renal disease (ESRD) patients pose several …

Surgical resection followed by radioactive iodine (131I) therapy constitutes a standard
treatment for differentiated thyroid cancer. 131I is normally excreted through the kidneys …

Radioactive iodine is utilized commonly for ablation of remnant thyroid tissue after
thyroidectomy and treatment of persistent disease and metastases in differentiated thyroid …